[ Price : $8.95]
FDA and the UK's Medicines and Healthcare products Regulatory Agency announce a new liaison program designed to strengthen collabo...[ Price : $8.95]
Eli Lilly reports positive Phase 3 results for its BTK inhibitor Jaypirca (pirtobrutinib) in combination with venetoclax and ritux...[ Price : $8.95]
Significant operational hurdles remain before FDA's Plausible Mechanism Framework can be broadly implemented, according to a comme...[ Price : $8.95]
FDA increases scrutiny of telehealth companies marketing compounded drugs, warning that some firms are making false or misleading ...[ Price : $8.95]
Neumora Therapeutics discontinues development of its lead depression candidate navacaprant after two Phase 3 studies failed to mee...[ Price : $8.95]
Jazz Pharmaceuticals says its Phase 3 LAGOON study evaluating Zepzelca (lurbinectedin) in relapsed small cell lung cancer failed t...[ Price : $8.95]
FDA approves AstraZeneca's AKT inhibitor Truqap (capivasertib) in combination with abiraterone and prednisone for adults with PTEN...[ Price : $8.95]
FDA posts a draft guidance to assist NDA sponsors in properly submitting patent information for listing in the agency's Orange Boo...